))
Investment Strategies in Phage Therapy with Dr. Richard Alm at CARB-X
Manage episode 315364571 series 3287704
Innhold levert av Steven Yang. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Steven Yang eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator(CARB-X) is one global nonprofit partnership that manages a large portfolio of early stage companies to do the job as described by its name. In this episode, we are happy to have its chief scientist Dr. Richard Alm to help us paint a broad picture of the antimicrobial landscape and discuss their investment strategies related to phage therapy. The global biotech is a $800B dollar market this year, with a >15% CAGR, what can we do to promote the scientific understanding of phage and phage therapy in this capital driven economy?
Find out more about CARB-X at their website: https://carb-x.org
19 episoder
Del
